Search

Your search keyword '"Drug Resistance, Neoplasm physiology"' showing total 2,685 results

Search Constraints

Start Over You searched for: Descriptor "Drug Resistance, Neoplasm physiology" Remove constraint Descriptor: "Drug Resistance, Neoplasm physiology"
2,685 results on '"Drug Resistance, Neoplasm physiology"'

Search Results

51. Targeting the tumour microenvironment in platinum-resistant ovarian cancer.

52. The hallmarks of ovarian cancer stem cells and niches: Exploring their harmonious interplay in therapy resistance.

53. ATP binding cassette transporters and cancer: revisiting their controversial role.

54. Exploring the clinical value of tumor microenvironment in platinum-resistant ovarian cancer.

55. Exosomal miR-27a-3p derived from tumor-associated macrophage suppresses propranolol sensitivity in infantile hemangioma.

56. ABCC5 facilitates the acquired resistance of sorafenib through the inhibition of SLC7A11-induced ferroptosis in hepatocellular carcinoma.

57. HER2 mediates clinical resistance to the KRAS G12C inhibitor sotorasib, which is overcome by co-targeting SHP2.

58. New approaches for targeting platinum-resistant ovarian cancer.

59. Potential Role of GST- π in Lung Cancer Stem Cell Cisplatin Resistance.

60. Overcoming Microenvironment-Mediated Chemoprotection through Stromal Galectin-3 Inhibition in Acute Lymphoblastic Leukemia.

61. ISL1 promotes enzalutamide resistance in castration-resistant prostate cancer (CRPC) through epithelial to mesenchymal transition (EMT).

62. Identification and Characterization of Senescence Phenotype in Lung Adenocarcinoma with High Drug Sensitivity.

63. Expression of inducible NOS is indispensable for the antiproliferative and proapoptotic effect of imatinib in BCR-ABL positive cells.

64. Interference between copper transport systems and platinum drugs.

65. Mechanisms of primary and acquired resistance to PD-1/PD-L1 blockade and the emerging role of gut microbiome.

66. RABL2A-CCDC34 Axis Promotes Sorafenib Resistance in Hepatocellular Carcinoma.

67. DKK1 suppresses WWP2 to enhance bortezomib resistance in multiple myeloma via regulating GLI2 ubiquitination.

68. Addressing Resistance to Targeted Therapies in Metastatic Colorectal Cancer.

69. COLOMATE challenge to overcome resistance in metastatic colorectal cancer.

70. FAT1 and PTPN14 Regulate the Malignant Progression and Chemotherapy Resistance of Esophageal Cancer through the Hippo Signaling Pathway.

71. Role of PI3K-AKT-mTOR Pathway as a Pro-Survival Signaling and Resistance-Mediating Mechanism to Therapy of Prostate Cancer.

72. BET Proteins as Attractive Targets for Cancer Therapeutics.

73. Cancer-associated fibroblasts induce monocytic myeloid-derived suppressor cell generation via IL-6/exosomal miR-21-activated STAT3 signaling to promote cisplatin resistance in esophageal squamous cell carcinoma.

74. Androgen receptor (AR) heterogeneity in prostate cancer and therapy resistance.

75. Effect of EPA on Hsp90 and GRα protein expression in multiple myeloma drug-resistant cells.

76. MicroRNA-495/TGF-β/FOXC1 axis regulates multidrug resistance in metaplastic breast cancer cells.

77. Roles of circRNAs in cancer chemoresistance (Review).

78. Role of epidermal growth factor receptor signaling in a Pt(II)-resistant human breast cancer cell line.

79. Impact of hypoxia on the pathogenesis and therapy resistance in multiple myeloma.

80. Discovery of MTR-106 as a highly potent G-quadruplex stabilizer for treating BRCA-deficient cancers.

81. Antioxidant responses related to temozolomide resistance in glioblastoma.

82. FGFR leads to sustained activation of STAT3 to mediate resistance to EGFR-TKIs treatment.

83. miR-221 confers lapatinib resistance by negatively regulating p27 kip1 in HER2-positive breast cancer.

84. Overexpression of long non-coding RNA urothelial carcinoma associated 1 causes paclitaxel (Taxol) resistance in colorectal cancer cells by promoting glycolysis.

85. TIP30 overcomes gefitinib resistance by regulating cytoplasmic and nuclear EGFR signaling in non-small-cell lung cancer.

86. Inhibition of AKR1B10-mediated metabolism of daunorubicin as a novel off-target effect for the Bcr-Abl tyrosine kinase inhibitor dasatinib.

87. USP32 confers cancer cell resistance to YM155 via promoting ER-associated degradation of solute carrier protein SLC35F2.

88. Metabolic reprograming confers tamoxifen resistance in breast cancer.

89. Circ_PIP5K1A regulates cisplatin resistance and malignant progression in non-small cell lung cancer cells and xenograft murine model via depending on miR-493-5p/ROCK1 axis.

90. Cisplatin induces autophagy-associated apoptosis in human oral squamous cell carcinoma (OSCC) mediated in part through reactive oxygen species.

91. Fatty acid oxidation and autophagy promote endoxifen resistance and counter the effect of AKT inhibition in ER-positive breast cancer cells.

92. The synergy between miR-486-5p and tamoxifen causes profound cell death of tamoxifen-resistant breast cancer cells.

93. Drug resistance in pituitary tumours: from cell membrane to intracellular signalling.

94. Landscape of extracellular vesicles in the tumour microenvironment: Interactions with stromal cells and with non-cell components, and impacts on metabolic reprogramming, horizontal transfer of neoplastic traits, and the emergence of therapeutic resistance.

95. CUL4 high Lung Adenocarcinomas Are Dependent on the CUL4-p21 Ubiquitin Signaling for Proliferation and Survival.

96. Oncogene-independent resistance in Philadelphia chromosome - positive (Ph + ) acute lymphoblastic leukemia (ALL) is mediated by activation of AKT/mTOR pathway.

97. Beyond Single-Cell Analysis of Metallodrugs by ICP-MS: Targeting Cellular Substructures.

98. Battling Chemoresistance in Cancer: Root Causes and Strategies to Uproot Them.

99. The component of the m 6 A writer complex VIRMA is implicated in aggressive tumor phenotype, DNA damage response and cisplatin resistance in germ cell tumors.

100. Aberrant activation of the CD45-Wnt signaling axis promotes stemness and therapy resistance in colorectal cancer cells.

Catalog

Books, media, physical & digital resources